CMS will be changing reimbursement practices regardless of how healthcare reform plays out
Rita Numerof, PhD, Numerof & Associates, Inc.
Advertisement
Articles by Rita Numerof, PhD, Numerof & Associates, Inc.
The most basic impulse behind CER is the desire to control healthcare costs. The implications for the biopharma industry could be significant
Advertisement
Latest Updated Articles
- Getting Ready for Comparative Effectiveness Research
Published: August 22nd 2009 | Updated:
- Follow the Money... Where Healthcare Policy is Headed
Published: April 10th 2010 | Updated:
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
Pharma Pulse: Alkermes Acquires Avadel in $2.1B Deal, BioNTech Moves to Buy CureVac, and MedTech Industry Embraces Digital-First Models
2
Cambrex Commits $120 Million to Grow US API Manufacturing
3
How Biopharma Companies Can Optimize Field Reimbursement Models
4
BioNTech Launches Public Exchange Offer for CureVac in $1.25B All-Stock Deal
5
